GLP-1s & eating disorders: a complicated relationship

Summary of GLP-1s & eating disorders: a complicated relationship

by NPR

21m•May 27, 2026
Listen to Episode

Overview of GLP-1s & eating disorders: a complicated relationship

This NPR It’s Been a Minute episode examines the complicated intersection of GLP-1 medications (like Ozempic, Wegovy, and semaglutide) and eating disorders. While these drugs can be life-changing for people with diabetes, obesity-related health issues, or binge-eating symptoms, the episode highlights how they can also be risky for people with restrictive eating disorders or those in recovery. Through reporting and expert commentary, the conversation explores how easy these drugs are to access, how they may affect food thoughts and body image, and why they’re becoming especially fraught in a culture increasingly obsessed with thinness.

Main themes and discussion points

  • GLP-1s are being used for many purposes

    • Originally designed for diabetes and blood sugar control.
    • Also showing promise for addiction and certain metabolic conditions.
    • Widely used for weight loss, which raises concerns in a culture already driven by thinness.

  • Eating disorder risk is central to the conversation

    • For people with eating disorders, appetite suppression and rapid weight loss can be dangerous.
    • GLP-1s may reduce bingeing for some users, but can also intensify restriction and trigger relapse.
    • Eating disorders are often fluid and do not fit neatly into a single diagnosis over time.

  • Access can be alarmingly easy

    • Journalist Hannah Seo described how simple it was to get semaglutide through a telehealth platform.
    • Safeguards were minimal and mostly self-reported.
    • A photo check for underweight status is not enough, since eating disorders can occur at any body size.

  • The drugs can be both helpful and harmful

    • For some, GLP-1s reduce “food noise” and give them breathing room to work on emotional and psychological issues.
    • For others, they reinforce restrictive patterns and intensify body-focused anxiety.
    • The effect seems highly individual and difficult to predict in advance.

Expert perspectives

Allegra Broft, psychiatrist and eating disorder specialist

  • Described GLP-1s as the latest version of a longstanding category of weight-control tools, akin to “diet pills,” but more potent.
  • Emphasized that food becoming “more neutral” can be a benefit for some and a loss of joy for others.
  • Warned that clinicians need to pay close attention when patients say a steep drop in appetite is “not restriction.”
  • Noted that many patients may not want to look closely at potential downsides when they feel the medication is helping.

Hannah Seo, journalist

  • Reported that GLP-1 access is often not meaningfully screened for eating-disorder history.
  • Shared the story of “Lily,” a woman with a long history of anorexia who later developed binge eating disorder and found GLP-1s both relieving and triggering.
  • Highlighted the idea that some people may use GLP-1s temporarily to create enough stability to heal their relationship with food.

Cultural and social implications

  • Thinness pressure is still pervasive

    • The episode argues that the “thin ideal” never really disappeared.
    • GLP-1s may be reinforcing the idea that people should be able to shrink if they really want to.
    • This can intensify shame and comparison for people in recovery.

  • Recovery becomes harder in a GLP-1-saturated environment

    • People recovering from eating disorders are constantly exposed to visible weight loss in others.
    • The episode compares this to recovery from alcoholism: just as someone may need time before being around alcohol, someone in eating-disorder recovery may need space before being around GLP-1 use and the body changes it creates.

  • The discussion around The Cut article showed how judgmental this topic can become

    • The hosts discuss backlash to a writer who said she cut off a friend using Wegovy while in recovery.
    • They argue that people often underestimate how consuming and destabilizing eating-disorder thoughts can be.

Key takeaways

  • GLP-1s are not inherently good or bad; their impact depends heavily on the person using them.
  • For people with eating disorders, especially restrictive disorders or mixed histories, these drugs can be risky and should be approached carefully.
  • Better screening, more open conversations, and easier access to mental health support are needed.
  • The episode suggests that the current system often makes it easier to get a GLP-1 than to get therapy.
  • Ultimately, the conversation is less about the medication alone and more about the broader culture of dieting, thinness, and how hard it is to recover in that environment.

Bottom line

The episode presents GLP-1s as a powerful but ethically and clinically complicated tool. They can reduce distress and improve health for many people, but in the context of eating disorders and diet culture, they can also worsen harmful patterns. The core message: more honesty, better screening, and more support are needed as these medications become increasingly common.